Deep-learning model determines breast tumor staging
A deep-learning model based on mammographic images can determine tumor staging and sentinel lymph node metastasis in breast cancer patients, a study published April 15 in Informatics in Medicine Unlocked found. A team led by Elaheh Tarighati Sereshkeh from the Iran University of Medical Science in Tehran found that its convolutional neural network (CNN) model achieved high performance marks in these areas. “This method can be used as a potential non-invasive tool to determine tumor staging and sentinel lymph node metastasis in breast cancer in people suspected of having the complication and to avoid unnecessary surger...
Source: AuntMinnie.com Headlines - April 16, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Artificial Intelligence Source Type: news
Monitoring ctDNA Predicts HER2+ Cancer Treatment Response Monitoring ctDNA Predicts HER2+ Cancer Treatment Response
Tracking a patient ' s circulating tumor DNA (ctDNA) can offer insight into how well-targeted therapies work in the early stages of treatment for HER2-positive cancers.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Negative axillary ultrasound can lead to breast biopsy omission
Many women with early-stage HR+HER2- breast cancer and a negative presurgical axillary ultrasound can skip sentinel lymph node biopsy, a study presented April 11 at the American Society of Breast Surgeons Annual Meeting in Orlando, FL, found.
In his talk, Andreas Giannakou, MD, from Brigham & Women’s Hospital and Harvard Medical School in Boston showed results suggesting that nodal disease burden and oncologic outcomes among women in a real-world setting are similar to criteria in the Sentinel Node vs. Observation After Axillary UltraSound (SOUND) trial.
“Although our follow-up is limited, oncologic outcomes are exce...
Source: AuntMinnie.com Headlines - April 12, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Womens Imaging Source Type: news
Breastfeeding saved my life: New mother learns she has stage 3 CANCER after difficulty producing milk
Lauren da Silva, 39, of New Jersey, had just found out that she was pregnant with her second son, Ryan, when she was diagnosed with stage three HER2-positive breast cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - April 9, 2024 Category: Consumer Health News Source Type: news
FDA Expands Enhertu Indication to HER2-Positive Solid Tumors FDA Expands Enhertu Indication to HER2-Positive Solid Tumors
The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
HER2-positive breast cancer: What is it?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - April 9, 2024 Category: Consumer Health News Source Type: news
AstraZeneca, Daiichi Drug gets broad tumor approval in US
Enhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread throughout the body, marking a breakthrough in cancer treatment. It's the first antibody drug conjugate with such wide clearance, offering new hope for patients with limited treatment options. AstraZeneca anticipates further growth opportunities. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 8, 2024 Category: Pharmaceuticals Source Type: news
Enhertu Approved in the US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
April 6, 2024 -- AstraZeneca and Daiichi Sankyo ' s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 6, 2024 Category: Drugs & Pharmacology Source Type: news
Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers
(MedPage Today) -- The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.
The action represents the... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 5, 2024 Category: American Health Source Type: news
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
DUBLIN, April 2, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 2, 2024 Category: Drugs & Pharmacology Source Type: news
Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
2 April 2024 -- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 2, 2024 Category: Drugs & Pharmacology Source Type: news
Ribociclib + Nonsteroidal Aromatase Inhibitor Benefits Early Breast Cancer
THURSDAY, March 21, 2024 -- Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) significantly improves invasive disease-free survival among patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2024 Category: Pharmaceuticals Source Type: news
Olivia Munn was diagnosed with breast cancer 2 months after a normal mammogram. This is the tool she says ‘saved my life’
Olivia Munn had a double mastectomy last year after being diagnosed with an “aggressive, fast-moving” form of breast cancer, she announced on Instagram Wednesday. She called herself “lucky” after a near-miss diagnosis. Women who have mutations in their BRCA1 and/or BRCA2 genes are at increased…#oliviamunn #thaïsaliabadi #gailmodel #her2 #mayoclinic #nci #noneyour #nonehowmany #brca2 #alaskannative (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2024 Category: Consumer Health News Source Type: news
High-Risk HR+/HER2- EBC High-Risk HR+/HER2- EBC
Importance of risk prognostication in HR+/ HER2- EBCMedscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Is Your Early Breast Cancer (EBC) Patient At High Risk of Recurrence? Is Your Early Breast Cancer (EBC) Patient At High Risk of Recurrence?
Clinicopathologic risk assessment and adherence support in patients with high-risk HR+/HER2- early breast cancerMedscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 7, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
